REGN

Regeneron Pharmaceuticals
D

REGN

Arincen73/100B

Regeneron Pharmaceuticals operating income 1990–2026

Regeneron Pharmaceuticals's operating income in Q3 FY2026, the three months to 30 September 2026, was 2.05B USD, up 99.5% on the same quarter a year before. Regeneron Pharmaceuticals's operating income over the last twelve months was 4.99B USD, up 35.3% on the twelve months before. In fiscal year 2025 it was 3.58B USD, down 10.3% on the year before.

Last updated 6 Nov 2026 · Next report 28 Jan 2027

Operating income

Operating income · +11.1% a year over 10 yearsOperating margin

Growth

Fiscal yearPeriod endingOperating incomeGrowthOperating marginGross profitGross marginEBITDA
TTM30 Sept 20264.99B+35.34%29.54%14.49B85.77%6.25B
FY202531 Dec 20253.58B-10.34%24.95%12.24B85.35%5.82B
FY202431 Dec 20243.99B-8.23%28.10%12.23B86.13%5.32B
FY202331 Dec 20234.35B-19.26%33.15%10.87B82.89%4.69B
FY202231 Dec 20225.39B-39.80%44.24%10.47B85.99%5.26B
FY202131 Dec 20218.95B+150.15%55.67%13.35B83.05%9.67B
FY202031 Dec 20203.58B+61.85%42.09%7.14B84.04%4.10B
FY201931 Dec 20192.21B-12.81%33.70%5.58B85.13%2.67B
FY201831 Dec 20182.53B+21.87%37.77%6.13B91.32%2.73B
FY201731 Dec 20172.08B+56.27%35.41%5.33B90.76%2.25B
FY201631 Dec 20161.33B+6.30%27.38%4.46B91.68%1.44B
FY201531 Dec 20151.25B+51.95%30.51%3.64B88.61%1.31B
FY201431 Dec 2014823.92M+10.88%29.22%2.56B90.86%865.81M
FY201331 Dec 2013743.05M+61.35%35.30%1.91B90.66%801.00M
FY201231 Dec 2012460.51M—33.41%1.26B91.19%496.67M
FY201131 Dec 2011-205.16M—-46.02%410.53M92.08%-170.53M
FY201031 Dec 2010-97.47M—-21.23%437.29M95.26%-75.66M
FY200931 Dec 2009-74.10M—-19.54%363.34M95.80%-55.37M
FY200831 Dec 2008-89.83M—-37.67%226.25M94.88%-61.32M
FY200731 Dec 2007-114.45M—-91.55%0.000.00%-82.07M
FY200631 Dec 2006-107.31M—-169.13%40.71M64.16%-76.52M
FY200531 Dec 2005-124.42M-2,303.70%-187.97%41.13M62.14%-67.90M
FY200431 Dec 20045.65M—3.24%22.71M13.05%69.24M
FY200331 Dec 2003-99.99M—-173.90%50.82M88.39%-91.51M
FY200231 Dec 2002-121.95M—-554.63%15.51M70.52%-113.50M
FY200131 Dec 2001-85.68M—-389.95%15.46M70.38%-79.61M
FY200031 Dec 2000-25.28M—-42.64%43.71M73.74%-20.86M
FY199931 Dec 1999-23.80M—-68.99%30.90M89.57%-20.40M
FY199831 Dec 1998-12.50M—-32.72%33.20M86.91%-9.50M
FY199731 Dec 1997-7.50M—-22.66%30.50M92.15%-9.30M
FY199631 Dec 1996-17.30M—-71.78%23.00M95.44%-11.20M
FY199531 Dec 1995-7.60M—-27.74%27.40M100.00%-1.70M
FY199431 Dec 1994-29.20M—-125.86%23.20M100.00%-25.00M
FY199331 Dec 1993-38.80M—-366.04%10.60M100.00%-35.70M
FY199231 Dec 1992-18.30M—-159.13%11.50M100.00%-16.30M
FY199131 Dec 1991-9.60M—-131.51%-5.50M-75.34%-8.80M
FY199031 Dec 1990-3.30M—-66.00%-1.30M-26.00%-3.00M

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

See also:Revenue,Net income,EPS,Shares outstanding,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Regeneron Pharmaceuticals's operating income

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.